.Nature Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA confirmation after an adverse test, which highlights the numerous complexities and also challenges of drug progression in this particular setup.